Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma

Abstract The advent of genomics has led to the identification of specific “driver” mutations in oncogenic kinases, and the development of targeted small molecule inhibitors to block their tumor-driving functions. These specific inhibitors have been a clinical success, and often significantly prolong...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dana S. Neel, Trever G. Bivona
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/0533102711904302b1f2fc1f1df3168a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0533102711904302b1f2fc1f1df3168a
record_format	dspace
spelling	oai:doaj.org-article:0533102711904302b1f2fc1f1df3168a2021-12-02T14:18:34ZResistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma10.1038/s41698-017-0007-02397-768Xhttps://doaj.org/article/0533102711904302b1f2fc1f1df3168a2017-03-01T00:00:00Zhttps://doi.org/10.1038/s41698-017-0007-0https://doaj.org/toc/2397-768XAbstract The advent of genomics has led to the identification of specific “driver” mutations in oncogenic kinases, and the development of targeted small molecule inhibitors to block their tumor-driving functions. These specific inhibitors have been a clinical success, and often significantly prolong the lives of individuals with cancer. Inevitably, however, the treated tumors recur as resistance to these targeted therapies develops. Here, we review the major mechanisms by which a cancer cell can evade targeted therapy, focusing on mechanisms of resistance to kinase inhibitors in lung cancer. We discuss the promising concept of rational upfront polytherapy in lung cancer, which involves concurrently targeting multiple proteins in critical signaling pathways in a cancer cell to prevent or delay resistance.Dana S. NeelTrever G. BivonaNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Precision Oncology, Vol 1, Iss 1, Pp 1-6 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Dana S. Neel Trever G. Bivona Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
description	Abstract The advent of genomics has led to the identification of specific “driver” mutations in oncogenic kinases, and the development of targeted small molecule inhibitors to block their tumor-driving functions. These specific inhibitors have been a clinical success, and often significantly prolong the lives of individuals with cancer. Inevitably, however, the treated tumors recur as resistance to these targeted therapies develops. Here, we review the major mechanisms by which a cancer cell can evade targeted therapy, focusing on mechanisms of resistance to kinase inhibitors in lung cancer. We discuss the promising concept of rational upfront polytherapy in lung cancer, which involves concurrently targeting multiple proteins in critical signaling pathways in a cancer cell to prevent or delay resistance.
format	article
author	Dana S. Neel Trever G. Bivona
author_facet	Dana S. Neel Trever G. Bivona
author_sort	Dana S. Neel
title	Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
title_short	Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
title_full	Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
title_fullStr	Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
title_full_unstemmed	Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
title_sort	resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/0533102711904302b1f2fc1f1df3168a
work_keys_str_mv	AT danasneel resistanceisfutileovercomingresistancetotargetedtherapiesinlungadenocarcinoma AT trevergbivona resistanceisfutileovercomingresistancetotargetedtherapiesinlungadenocarcinoma
_version_	1718391587073949696

Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma

Ejemplares similares